• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Medtronic touts 2-year study results for In.Pact AV drug-coated balloon

April 20, 2021 By Sean Whooley

Medtronic logo updatedMedtronic (NYSE:MDT) today touted safety and effectiveness results from a 24-month study of its In.Pact AV drug-coated balloon.

Fridley, Minn.-based Medtronic said in a news release that the data demonstrated that the In.Pact AV DCB is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity.

The In.Pact AV Access prospective, global, single-blinded randomized controlled trial enrolled 330 subjects across 29 sites in the U.S., Japan and New Zealand. Six-month data demonstrating that the DCB reached primary endpoints were presented in September 2019.

Over two years, the group in the trial receiving treatment with the In.Pact AV DCB demonstrated a continued clinical benefit compared to the PTA control group. Target lesion primary patency through 24 months came in at 52.2% in the In.Pact AV group, compared to 36.2% in the PTA control group.

Additionally, access circuit primary patency was 39.5% in the In.Pact AV group, topping the 25.4% registered in the PTA control. However, freedom from all-cause mortality through 24 months was 82.4% in the In.Pact AV group, compared to a slightly better 82.8% in the PTA control group.

“Medtronic is committed to providing physicians and patients with technology to improve dialysis access maintenance outcomes and reduce disruptions to care. Both our investment in this study as well as its results are a clear testament to this,” Medtronic president of the peripheral vascular health business Dave Moeller said in the release. “These results are significant not only because In.Pact AV is the only DCB to meet both safety and effectiveness endpoints through six months, but also because it demonstrates that at two years, In.Pact AV does better than PTA in helping to keep critical lifelines open and reduce the number of times a patient needs to return to their physician for a reintervention.”

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured Tagged With: Medtronic

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS